人GM-CSF基因转染小鼠肝癌细胞及其致瘤性研究

DECRASED TUMORIGENICITY OF TUMOR VACCINE TRANSFECTED WITH HUMAN GM-CSF GENE VIA RECOMBINANT ADKENOVIRAL VECTORS

为建立以腺病毒为载体的GM－CSF基因转染瘤苗，并研究其体内抗肿瘤作用，应用携带有人GM－CSF基因的重组腺病毒（R－Ad5）载体转染BALB／c小鼠肝癌细胞株（H22），体外应用酶联免疫吸附试验（ELISA法）．检测GM－CSF表达水平，以GM—CSF基因转染的H22细胞进行致癌性研究。结果：（1）重组腺病毒载体能成功地介导GM－CSF基因转染H22细胞并能持续有效表达26～31天，瘤苗的辐照处理并不明显影响GM－CSF表达水平。（2）GM－CSF基因转染瘤苗体内致癌性显著降低。该结果揭示了应用GM－CSF基因转来瘤苗进行肿瘤基因治疗的可行性，为进一步研究肿瘤的GM－CSF基因治疗提供了依据．

In order to generate cancer vaccine trans fected with GM-CSF gene via recombinant adenoviral (R-Ad5) vectors and to examine the antitumor effect of cancer vaccine, R-Ad5 vectors contain ing the gene for human GM - CSF are used to infect H22 cells, a hepatocellu1ar carcinoma cell line of BALB/c mice origin. GM-CSF production was measured in vitro by enzyme-linked immunosorbent assay (ELISA). Tumorigenicity. of H22 cells trans fected with GM -CSF genevia R-Ad5 vectors was studied.The results showed that R-Ad5, vectors could successfully carry GM -CSF gene into H22 cells and efficiently espress for 26 to 31 days. Irradiation did not abolish secretion of sufficient GM-CSF levels. Secretion of GM -CSF from the tum0r cells abrogated their tumorigenicity. Our resu1ts indicates the feasibility of cancer gene therapy with expression of GM - CSF gene in tumor cell pr0vided a basis for further investigation on cancer vaccine.